[{"abstract": "The late-trial success of telaprevir has given medical experts reason to believe a new wave of drugs could lead to far better treatment outcomes for patients who have the virus.", "web_url": "https://www.nytimes.com/2010/07/22/business/22hepatitis.html", "snippet": "The late-trial success of telaprevir has given medical experts reason to believe a new wave of drugs could lead to far better treatment outcomes for patients who have the virus.", "lead_paragraph": " New medicines are being developed that are expected to transform the care of patients with hepatitis C, making treatment far more effective and far less grueling.", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2010/07/22/business/22hepatitis1/22hepatitis1-articleLarge.jpg", "height": 330, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2010/07/22/business/22hepatitis1/22hepatitis1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 330}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2010/07/22/business/22hepatitis1/22hepatitis1-jumbo.jpg", "height": 682, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2010/07/22/business/22hepatitis1/22hepatitis1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2010/07/22/business/22hepatitis1/22hepatitis1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}], "headline": {"main": "Hope Against Hepatitis C", "kicker": null, "content_kicker": null, "print_headline": "Hope Against Hepatitis C", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Vertex Pharmaceuticals Incorporated", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Merck & Company Inc", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Medicine and Health", "rank": 4, "major": "N"}, {"name": "subject", "value": "Hepatitis", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Roche Holding AG", "rank": 6, "major": "N"}], "pub_date": "2010-07-22T00:02:20+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/0158e5da-87ab-5828-9b47-501b6e20d146", "word_count": 1407, "uri": "nyt://article/0158e5da-87ab-5828-9b47-501b6e20d146"}, {"abstract": "A little more than a year after acquiring Genentech, Roche said Thursday that its profits for the first half of this year had risen by 37 percent from the same period a year before as exceptional costs associated with the merger had fallen.", "web_url": "https://dealbook.nytimes.com/2010/07/22/roche-profit-up-on-genentech-synergies/", "snippet": "A little more than a year after acquiring Genentech, Roche said Thursday that its profits for the first half of this year had risen by 37 percent from the same period a year before as exceptional costs associated with the merger had fallen.", "lead_paragraph": "A little more than a year after acquiring Genentech, Roche said Thursday that its profits for the first half of this year had risen by 37 percent from the same period a year before as exceptional costs associated with the merger had fallen.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Roche Profit Up on Genentech Synergies", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "persons", "value": "Schwan, Severin", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Genentech Inc", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Merck & Company Inc", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Roche Holding AG", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Wyeth", "rank": 6, "major": "N"}, {"name": "glocations", "value": "San Francisco (Calif)", "rank": 7, "major": "N"}, {"name": "glocations", "value": "Switzerland", "rank": 8, "major": "N"}], "pub_date": "2010-07-22T08:34:25+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Chris V. Nicholson", "person": [{"firstname": "Chris", "middlename": "V.", "lastname": "Nicholson", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "", "_id": "nyt://article/d3bbca8e-689d-5f68-8066-894ff8837a73", "word_count": 232, "uri": "nyt://article/d3bbca8e-689d-5f68-8066-894ff8837a73"}]